Q-omics provides the consensus-scored C21orf91 profile across patient tissues and cancer cell-line models. C21orf91 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C21orf91 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, C21orf91 RNA expression shows 20,193 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where C21orf91 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C21orf91 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C21orf91 survival associations across molecular data types. C21orf91 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C21orf91 RNA expression–survival associations across cancer types. High C21orf91 expression shows unfavorable associations in UVM, but favorable associations in HNSC, KIRC, LUSC, THYM and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for C21orf91 RNA expression.
This table summarizes C21orf91 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C21orf91. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C21orf91 shows lower tumor expression in KICH, LIHC, BRCA and LUAD and higher tumor expression in HNSC and LUSC. The KICH box plot shows higher C21orf91 RNA expression in normal versus tumor tissue (log2 FC = −1.029, t-test p < 0.001).
This table shows molecular features associated with C21orf91 in patient tissues and cancer cell lines. In patient samples, C21orf91 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C21orf91 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
